Omai Gold Intersects Multiple Gold Zones in Each Wenot Hole Including 4.84 g/t Au over 38.4m and 12.57 g/t Au over 5.8m

BAE Systems (BA.L) secured a $138M U.S. Navy contract for Virginia-class submarine propulsor assemblies, covering production, services, and parts until 2032. The company meets the Navy's annual production target and has supplied all submarines to date. Shares fell 1.36% to 1,891.50p on LSE.

Merck (MRK) and Moderna (MRNA) plan to file intismeran for melanoma this year, with trial data showing a 42% reduction in recurrence or death risk. Merck expects earnings guidance for 2027 on Feb. 2, with analysts forecasting flat EPS of $8.98. Keytruda, Merck's top-selling drug, faces patent expiration in 2028. Merck trades at 17.5x forward earnings, above its five-year average.

BAE Systems completed Lot 8 RF sensor deliveries to Lockheed Martin for the US military’s LRASM program, following investments in electronic warfare facilities. The sensors enable the missile to target ships in complex environments. BAE Systems is contracted to supply these sensors through 2028, with production expected to increase from 2026. The company also upgraded the sensor’s software to enhance capabilities.

Bank of America analyst Vivek Arya lowered his price target for Intel (INTC) to $80 from $100, citing uncertainty about its 2027 CPU business and lack of progress in securing external customers for its foundry operations. The Hold rating was maintained.

Nvidia's finance chief, Colette Kress, will become interim CEO, replacing co-founder Jensen Huang, according to the company. The change follows a board decision to remove Huang from his role. Nvidia's processors are used in advanced supercomputers and AI data centers.

Pfizer received $1.5bn from Blackstone Life Sciences to fund the development of its obesity drug, berobenatide, through 2028. The drug is part of Pfizer's strategy to enter the obesity market, with 10 ongoing or planned Phase III studies. Blackstone will receive milestone payments but no ownership rights. Pfizer's CFO stated the funding will help advance their obesity program and maintain financial flexibility. Citi analysts noted the deal improves the program's risk-adjusted economics.